



PRODUCT: **Barostim™**

COMPANY: CVRx, Inc.

THERAPEUTIC AREA & INDICATION:

Treatment of Heart Failure with Reduced Ejection  
Fraction (HFrEF)

---

ABOUT THE PRODUCT

CVRx's Barostim Baroflex Activation Therapy is the first medical technology approved by the FDA that uses neuromodulation - the power of the brain and nervous system - to improve the symptoms of patients with systolic heart failure (HFrEF). Barostim is delivered by the Barostim NEO Generator™, an implantable device that uses CVRx-patented technology to send electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors trigger the body's baroreflex which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of HF. Barostim NEO received the FDA Breakthrough Device Designation and is FDA-approved for use in HF patients in the US. It has also received the CE Mark for HF and resistant hypertension in the European Economic Area. To learn more about Barostim, watch this video: <https://bit.ly/3xgvLZm>